Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Eton Pharmaceuticals, Inc.

NASDAQ: ETON · Life Sciences · 10 alerts · CIK 1710340

Eton Pharmaceuticals, Inc. stories on ALFA USA NewsRead the news →
Share price
$63.88Close, Nov 16
Market cap
$1.84B
Shares outstanding
28.84MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Eton Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:03 PM ET 8-K
Clinical Trial Data

Eton Pharmaceuticals Clinical Trial Data

Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.

“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”

Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.